Treatment of Primary Urethral Carcinoma with M1 Distant Metastasis
Clinical Scenario
This protocol applies to patients with primary urethral carcinoma confirmed at the M1 stage — disease that has spread to distant sites beyond the primary tumour and regional lymph nodes. At this advanced stage, systemic management takes precedence.
Patient Population
Primary urethral carcinoma with M1 (distant metastasis): tumour-derived spread to distant organs or structures. The histological subtype of the primary tumour is the key determinant in directing the treatment pathway for this patient population.
Treatment Approach (Partial Overview)
Systemic therapy is the primary modality at the M1 stage. The choice of regimen is driven by the histology of the tumour — different subtypes of primary urethral carcinoma are managed according to distinct, histology-specific evidence-based pathways.
Complete regimen selection, full treatment sequence, and all evidence-based options are detailed in the structured protocol →
References
- Systemic therapy in metastatic disease should be selected based on the histology of the tumour.
- The EAU MIBC Guidelines can be followed if UC is the predominant histology.
- An analysis of the SEER database reported that patients with M1 disease who underwent primary site surgery did not exhibit any survival benefit.
View source ↗